Abstract:R ed blood cells (RBCs) are nature’s long-circulating delivery vehicles. They possess various remarkable properties and continue to inspire the design and engineering of man-made delivery systems. Inherently suited for intravascular delivery, RBCs are intrinsically biocompatible, biodegradable, and nonimmunogenic. They form natural compartments capable of protecting encapsulated cargos, and this allows them to circulate in the bloodstream for a long period of time (up to 120 days). In addition, their semipermeable membrane affords sustained release to smallmolecule drugs, yet they are ideal for retaining large proteins while providing them access to the substrates. Delivery vehicles possessing one or several of these properties have long been desired for efficacious therapeutics. A long-sought strategy for RBC-mimicking delivery vehicles is to load natural RBCs with therapeutic agents without compromising the structural integrity and biological functions of the RBCs. Various loading techniques, including automated loading devices, have been developed to enable the encapsulation of payloads with molecular weights of over 180 kDa into RBCs with maintenance of the carriers’ biological competence. In addition to the interior of RBCs, their exterior surface has also been coupled with therapeutic molecules, either covalently or physically, for various delivery applications. These RBC-based delivery vehicles, namely carrier RBCs, have been developed for the delivery of numerous therapeutic agents, including proteins, nucleic acids, and small-molecule drugs. Several of them have entered clinical tests to treat various diseases, including cancers and enzyme deficiencies. Meanwhile, advances in molecular biology have provided unprecedented understanding of the connections between the physicochemical characteristics of RBCs and their biological functions. This understanding, in turn, has inspired researchers to model drug carriers after RBCs. Designs that mimic the physicochemical characteristics and biological functions of RBCs, particularly those that enable their passage through narrow constrictions while maintaining a long in vivo survival, have been integrated into the engineering of drug carriers and have resulted in novel delivery systems with improved drug tolerability, circulation lifetime, and efficacy. Recently, the pursuit of RBC-mimicking nanoparticles led us to develop an intriguing approach for functionalizing synthetic nanoparticles with natural RBC membranes. In this approach, we first collected intact cellular membranes and then coated them onto polymeric nanoparticle cores, such as those made from poly(lactic-co-glycolic acid) (PLGA); this resulted in red-blood-cell-membrane–coated nanoparticles (RBC-NPs; Figure 1). Our aim was to fabricate cellmimicking nanoparticles through a top-down approach that bypassed the labor-intensive processes of protein identification, purification, and conjugation. The natural membranes also provide a bilayered medium for transmembrane protein anchorage while preventing common chemical modifications that could compromise the integrity and functionalities of these proteins. The independent preparation of cellular membranes and particle cores before coating offers a new level of engineering flexibility toward highly functional biomimetic nanoparticles. Since their initial development, RBC-NPs have provided an unprecedented capability for harnessing the natural functionalities of native cells that would otherwise be difficult to replicate. They have since inspired us to develop novel nanotherapeutics for better disease intervention. In this Perspective, we review our recent progress in developing RBC-NPs for three distinct biomedical applications: long-circulating nanocarriers for drug delivery, biomimetic nanosponges for detoxification, and nanotoxoids for safe and effective toxin vaccination.

Red blood cell membrane-camouflaged prednisolone acetate-loaded PLGA nanoparticles for kidney-targeted drug delivery

Engineering red‐blood‐cell‐membrane–coated nanoparticles for broad biomedical applications

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

Recent Advances and Prospects for Lipid-Based Nanoparticles As Drug Carriers in the Treatment of Human Retinal Diseases

Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect

Immuno-Nanoparticles Developed Using Dexamethasone and Captopril Co-Loaded PLGA Improve Glomerulonephritis Through Modulating Macrophage Polarization

Co-Delivery of Dexamethasone and Captopril by α8 Integrin Antibodies Modified Liposome-PLGA Nanoparticle Hybrids for Targeted Anti-Inflammatory/Anti-Fibrosis Therapy of Glomerulonephritis

Kidney-targeted rhein-loaded liponanoparticles for diabetic nephropathy therapy via size control and enhancement of renal cellular uptake

Glomerulus-Targeted ROS-Responsive Polymeric Nanoparticles for Effective Membranous Nephropathy Therapy

Red Blood Cell Membrane Functionalized Biomimetic Nanoparticles for Systemic Lupus Erythematosus Treatment

Cysteine-modified PEGylated nanoparticles for targeted delivery of methylprednisolone to pancreatitis

Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer

Comparison of cell delivery and cell membrane camouflaged PLGA nanoparticles in the delivery of shikonin for colorectal cancer treatment

PEGylated Gambogic Acid Nanoparticles Enable Efficient Renal-Targeted Treatment of Acute Kidney Injury

Biomimetic-Coated Nanoplatform with Lipid-Specific Imaging and ROS Responsiveness for Atherosclerosis-Targeted Theranostics

Bovine Serum Albumin Nanoparticles for Delivery of Tacrolimus to Reduce Its Kidney Uptake and Functional Nephrotoxicity.

Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury

Dexamethasone Acetate‐Loaded PLGA Nanospheres Targeting Liver Macrophages

LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation

Erythrocyte Membrane-Wrapped Ph Sensitive Polymeric Nanoparticles for Non-Small Cell Lung Cancer Therapy.

Lipid-Insertion To Enable Targeting Functionalization Of Paclitaxel Loaded Erythrocyte Membrane Nanoparticle By Tumor-Penetrating Bispecific Recombinant Protein.